NCT01046955View on ClinicalTrials.gov

Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

December 31, 2008

Conditions
End-Stage Renal DiseaseLiving Donors
Interventions
DRUG

Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab

comparison of induction therapies.

Trial Locations (1)

33136

University of Miami Jackson Memorial Hospital, Miami

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University of Miami

OTHER

NCT01046955 - Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation | Biotech Hunter | Biotech Hunter